ANIPANI PHARMACEUTICALS INC
Pharmaceutical Preparations
- Revenue
- $883M
- 44% YoY
- Operating margin
- 12.6%
- 13130% YoY
- EBITDA
- $203M
- 196% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.1×
- −$226M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear237% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear7% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $216M | $316M | $487M | $614M | $883M | 44% |
| Operating income | −$40M | −$35M | $47M | $584K | $111M | 18923% |
| Net income | −$43M | −$48M | $19M | −$19M | $78M | 511% |
| Operating cash flow | $3M | −$31M | $119M | $64M | $185M | 189% |
| Capex | $3M | $9M | $9M | $16M | $14M | 15% |
| Stock-based comp | $10M | $15M | $21M | $29M | $38M | 29% |
| Buybacks | $890K | $2M | $5M | $11M | $12M | 11% |
| Dividends | $190K | $2M | $2M | $2M | $1M | 29% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 14
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 272 | 72 |
| FY2024 | — | — | 190 | 62 |
| FY2023 | — | — | 190 | 63 |
| FY2022 | — | — | 139 | 65 |
| FY2021 | — | — | 159 | 97 |